Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Duragesic Public Health Advisory Follows Palladone Withdrawal

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is investigating reports of deaths associated with overdoses of the fentanyl patch (J&J’s Duragesic and generics). As with Purdue’s opioid Palladone, alcohol consumption is cited as a possible factor in increased fentanyl release or effect.

You may also be interested in...



Limits Of FDA’s Risk Management Practices Shown In Renewed Duragesic Warnings

Fentanyl patch will get stronger labeling and a patient MedGuide, but FDA opts against a more interventionist approach as it issues its second public health advisory in two years about the risk of death.

Limits Of FDA’s Risk Management Practices Shown In Renewed Duragesic Warnings

Fentanyl patch will get stronger labeling and a patient MedGuide, but FDA opts against a more interventionist approach as it issues its second public health advisory in two years about the risk of death.

Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA

Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS062558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel